Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers

Table 2 Clinical data and demographics corresponding to CSF samples from subjects with or without G2019S-LRRK2 mutations, with or without PD

	LRRK2+/PD-	LRRK2+/PD+	LRRK2-/PD+	LRRK2-/PD-	p value^a
Gender M(F)	13(26)	3(16)	11(8)	0(5)	0.008
Age	63 (56-69)	57 (53-69)	60 (50-67)	60 (44.5-74)	ns
Age at onset	NA	55 (47-65)	57 (50-60)	NA	ns
LEDD	NA	600 (250-675)	300 (0-550)	NA	ns
UPDRS_III	5 (0-6)	18 (15-22)	20 (16.25-22)	0 (0-0)	<0.0001
MoCA	26 (26-28)	26 (25-27)	27 (26-28)	27 (<26-30)	ns
H&Y	0 (0-0)	2 (2-2.5)	2 (2-2)	0 (0-0)	<0.0001

LEDD is L-dopa equivalent daily dosage, UPDRS is Unified Parkinson’s Disease Rating Scale, MoCA is Montreal Cognitive Assessment, H&Y is Hoehn & Yahr scale, NA is not applicable; Values reported are group median (interquartile range). ^aDetermined by comparing LRRK2+/PD- to LRRK2+/PD+ using the Dunn post hoc test following Kruskal-Wallis test of all groups. ns is not significant as determined by Pearson chi square (MoCA), ANOVA (age at test), t test (age at onset), Mann-Whitney test (LEDD) and Kruskal-Wallis test (H&Y, UPDRS III)

ISSN: 2051-5960